Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC

A 2-year update of the CheckMate 9LA trial showed a sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC). The combination of nivolumab and ipilimumab, which have distinct but complementary mechanisms of action, has shown improved long-term overall survival benefit in advanced NSCLC [1]. In the randomised, phase 3 CheckMate 9LA trial (NCT03215706), first-line nivolumab plus ipilimumab combined with 2 cycles of chemotherapy significantly improved overall survival, progression-free survival, and objective response rate versus 4 cycles of chemotherapy alone [2]. Clinical benefit was observed regardless of PD-L1 expression level and histology. This regimen is now approved in th...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 12 August, 20213 September, 2021